Iron Chelators in Treatment of Iron Overload
Journal of Toxicology · 05.05.2022 · 2022 · 1-18
DOI: 10.1155/2022/4911205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Toxicology, erschienen am 05.05.2022. Verfasst von Sarina Entezari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patients suffering from iron overload can experience serious complications. In such patients, various organs, such as endocrine glands and liver, can be damaged. Although iron is a crucial element for life, iron overload can be potentially toxic for human cells due to its role in generating free radicals. In the past few decades, there has been a major improvement in the survival of patients who suffer from iron overload due to the application of iron chelation therapy in clinical practice. In clinical use, deferoxamine, deferiprone, and deferasirox are the three United States Food and Drug Administration-approved iron chelators. Each of these iron chelators is well known for the treatment of iron overload in various clinical conditions. Based on several up-to-date studies, this study explained iron overload and its clinical symptoms, introduced each of the above-mentioned iron chelators, and evaluated their advantages and disadvantages with an emphasis on combination therapy, which in recent studies seems a promising approach. In numerous clinical conditions, due to the lack of accurate indicators, choosing a standard approach for iron chelation therapy can be difficult; therefore, further studies on the issue are still required. This study aimed to introduce each of these iron chelators, combination therapy, usage doses, specific clinical applications, and their advantages, toxicity, and side effects.
Autor:innen und Institutionen
- Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Student Research Committee, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran.
- Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.
- Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID-Profile: Muhammad Islampanah, Niloofar Deravi
Zitieren
APA
Entezari, S., Haghi, S. M., Norouzkhani, N., Sahebnazar, B., Vosoughian, F., Akbarzadeh, D., Islampanah, M., Naghsh, N., Abbasalizadeh, M., & Deravi, N. (2022). Iron Chelators in Treatment of Iron Overload. Journal of Toxicology, 2022, 1-18. https://doi.org/10.1155/2022/4911205
Vancouver
Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D, et al. Iron Chelators in Treatment of Iron Overload. Journal of Toxicology. 2022;2022:1-18. doi:10.1155/2022/4911205
BibTeX
@article{Entezari2022,
author = {Entezari, Sarina and Haghi, Seyedeh Mona and Norouzkhani, Narges and Sahebnazar, Barsa and Vosoughian, Fatemeh and Akbarzadeh, Diba and Islampanah, Muhammad and Naghsh, Navid and Abbasalizadeh, Mohammad and Deravi, Niloofar},
title = {Iron Chelators in Treatment of Iron Overload},
journal = {Journal of Toxicology},
year = {2022},
volume = {2022},
pages = {1--18},
doi = {10.1155/2022/4911205}
}
EUVIMED